SB 385 (The Vax Act) requires Maryland’s Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services, aligning with guidance from major medical organizations like the CDC and U.S. Preventive Services Task Force. It expands pharmacists’ authority to administer vaccines (including those recommended by CDC or the Secretary) to patients aged 3+ after completing specific training and certification, while mandating health insurers to cover these services without cost-sharing. The bill also repeals outdated pertussis-related provisions and updates reporting requirements for pharmacists. This directly affects pharmacists, health insurers, and patients seeking preventive care, aiming to improve access to vaccinations and screenings.
SB 333 creates the Interstate Podiatric Medical Licensure Compact, allowing podiatrists (foot and ankle specialists) licensed in Maryland to practice in other participating states more easily. The bill establishes a streamlined process for obtaining an "expedited license" in multiple states without altering existing state licensing laws, requiring podiatrists to pass national exams and pass background checks. Crucially, it mandates that podiatrists follow the rules of the state where the patient is located during treatment, not where the provider is licensed. This compact directly affects licensed podiatrists seeking multi-state practice and state licensing boards overseeing medical practice.
SB 293 requires nursing homes, assisted living facilities, and nurse midwives to notify residents and prospective residents in writing if they lack professional liability insurance or if coverage has lapsed without renewal. For prospective residents, notification must occur at the first visit during a coverage gap or at the time of application; current residents must be notified within 30 days of a lapse. Facilities without coverage must also post a conspicuous notice visible to residents and guests. This law aims to increase transparency about insurance coverage for individuals receiving care in these settings.
SB 444 repeals an exemption that previously allowed intermediate care facilities offering substance use disorder treatment to change bed capacity without a certificate of need. It creates a new exemption for facilities providing *medically managed residential substance use disorder treatment services*, removing the requirement for a certificate of need if they submit 45 days' written notice to the Commission and the Commission determines the change aligns with the state health plan, improves service efficiency, and serves the public interest. This bill directly affects intermediate care facilities focused on substance use disorder treatment by reducing regulatory barriers for expanding bed capacity or establishing new facilities. The key mechanism is replacing a certificate of need with a streamlined notice-and-review process administered by the Commission. (SB 444, "Certificate of Need - Intermediate Health Care Facilities," 2026)
HB 1445, the "Maryland Protecting People With Disabilities Act," changes eligibility rules for home- and community-based services under Maryland's Medicaid program (Maryland Medical Assistance Program). It requires the state to continue services uninterrupted during appeals if an individual loses eligibility, prohibits automatic termination solely due to administrative errors (procedural disenrollment), and mandates data sharing between providers and the Department of Health. The bill directly affects people receiving Developmental Disabilities Administration services and Medicaid beneficiaries who risk losing community-based care due to eligibility disputes. Key provisions include extending appeal timelines (replacing 90-day deadlines with continuous service until appeal resolution) and requiring the state to reserve waiver slots for those who lost eligibility unfairly. These changes aim to align with the Olmstead v. L.C. Supreme Court ruling protecting community integration rights.
HB 797 prohibits employers from discriminating against fire and rescue public safety employees who use medical cannabis, provided they have a valid written certification from a licensed healthcare provider under Maryland's medical cannabis program. The bill modifies existing law to clarify that an employer cannot take adverse employment actions (like termination or denial of promotion) solely due to medical cannabis use, as long as the employee meets the state's certification requirements. It updates definitions in Maryland law to ensure fire and rescue employees qualify for the same protections as other medical cannabis patients under the existing program. The law does not override workplace safety rules or require employers to accommodate cannabis use during work hours.
SB 866 requires chain restaurants with 20 or more locations in Maryland to display warning icons next to menu items exceeding 1,150mg sodium or 25mg added sugars per serving, starting January 1, 2028. The Maryland Department of Health must create these icons and guidelines by January 1, 2027, and run a public education campaign during 2027 to explain compliance. The bill directly affects large chain restaurants by mandating clear labeling of high-sodium and high-sugar menu items. It defines "high sodium" as 1,150mg per serving and "high added sugars" as 25mg per serving for labeling purposes.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 598 creates a temporary license for internationally trained physicians to practice medicine in Maryland under specific conditions. It allows the State Board of Physicians to issue a 3-year license (non-renewable) to doctors who hold a WHO-recognized medical degree outside the U.S., completed 2 years of equivalent postgraduate training, practiced medicine for 5 of the last 7 years abroad, passed U.S. medical exams (USMLE Steps 1-3), and meet other criteria like English proficiency and Maryland residency. The license requires physicians to pursue full licensure through board-established pathways after the temporary period ends. This directly affects internationally trained doctors seeking to work in Maryland’s healthcare system, providing a structured but limited pathway to practice.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
